awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q26766240-3B450D5B-D00C-4A7E-81A9-04F764114E11
Q26766240-3B450D5B-D00C-4A7E-81A9-04F764114E11
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26766240-3B450D5B-D00C-4A7E-81A9-04F764114E11
Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma
P2860
Q26766240-3B450D5B-D00C-4A7E-81A9-04F764114E11
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26766240-3B450D5B-D00C-4A7E-81A9-04F764114E11
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
a5e8df6037f2023b1826e57b3415ce504bc09ddf
P2860
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.